125 related articles for article (PubMed ID: 36789652)
21. FUT8 is regulated by miR-122-5p and promotes malignancies in intrahepatic cholangiocarcinoma via PI3K/AKT signaling.
Chen F; Li Y; Aye L; Wu Y; Dong L; Yang Z; Gao Q; Zhang S
Cell Oncol (Dordr); 2023 Feb; 46(1):79-91. PubMed ID: 36348252
[TBL] [Abstract][Full Text] [Related]
22. The Tumor Microenvironment Drives Intrahepatic Cholangiocarcinoma Progression.
Mancarella S; Serino G; Coletta S; Armentano R; Dituri F; Ardito F; Ruzzenente A; Fabregat I; Giannelli G
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457006
[TBL] [Abstract][Full Text] [Related]
23. In vivo evidence for GDP-fucose transport in the absence of transporter SLC35C1 and putative transporter SLC35C2.
Lu L; Varshney S; Yuan Y; Wei HX; Tanwar A; Sundaram S; Nauman M; Haltiwanger RS; Stanley P
J Biol Chem; 2023 Dec; 299(12):105406. PubMed ID: 38270391
[TBL] [Abstract][Full Text] [Related]
24. Epigenetic upregulation of TET2 is an independent poor prognostic factor for intrahepatic cholangiocarcinoma.
Yamashita H; Tourna A; Akita M; Itoh T; Chokshi S; Ajiki T; Fukumoto T; Youngson NA; Zen Y
Virchows Arch; 2022 May; 480(5):1077-1085. PubMed ID: 34905094
[TBL] [Abstract][Full Text] [Related]
25. 6-alkynyl fucose is a bioorthogonal analog for O-fucosylation of epidermal growth factor-like repeats and thrombospondin type-1 repeats by protein O-fucosyltransferases 1 and 2.
Al-Shareffi E; Chaubard JL; Leonhard-Melief C; Wang SK; Wong CH; Haltiwanger RS
Glycobiology; 2013 Feb; 23(2):188-98. PubMed ID: 23045360
[TBL] [Abstract][Full Text] [Related]
26. Fragile X mental retardation protein in intrahepatic cholangiocarcinoma: regulating the cancer cell behavior plasticity at the leading edge.
Carotti S; Zingariello M; Francesconi M; D'Andrea L; Latasa MU; Colyn L; Fernandez-Barrena MG; Flammia RS; Falchi M; Righi D; Pedini G; Pantano F; Bagni C; Perrone G; Rana RA; Avila MA; Morini S; Zalfa F
Oncogene; 2021 Jun; 40(23):4033-4049. PubMed ID: 34017076
[TBL] [Abstract][Full Text] [Related]
27. Filamin A is involved in human intrahepatic cholangiocarcinoma aggressiveness and progression.
Vitali E; Franceschini B; Milana F; Soldani C; Polidoro MA; Carriero R; Kunderfranco P; Trivellin G; Costa G; Milardi G; Di Tommaso L; Torzilli G; Lleo A; Lania AG; Donadon M
Liver Int; 2024 Feb; 44(2):518-531. PubMed ID: 38010911
[TBL] [Abstract][Full Text] [Related]
28. Sulforaphane Potentiates Gemcitabine-Mediated Anti-Cancer Effects against Intrahepatic Cholangiocarcinoma by Inhibiting HDAC Activity.
Tomooka F; Kaji K; Nishimura N; Kubo T; Iwai S; Shibamoto A; Suzuki J; Kitagawa K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
Cells; 2023 Feb; 12(5):. PubMed ID: 36899823
[TBL] [Abstract][Full Text] [Related]
29. Intrahepatic cholangiocarcinoma: typical features, uncommon variants, and controversial related entities.
Zen Y
Hum Pathol; 2023 Feb; 132():197-207. PubMed ID: 35697170
[TBL] [Abstract][Full Text] [Related]
30. The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma.
Di Matteo S; Nevi L; Costantini D; Overi D; Carpino G; Safarikia S; Giulitti F; Napoletano C; Manzi E; De Rose AM; Melandro F; Bragazzi M; Berloco PB; Giuliante F; Grazi G; Giorgi A; Cardinale V; Adorini L; Gaudio E; Alvaro D
PLoS One; 2019; 14(1):e0210077. PubMed ID: 30677052
[TBL] [Abstract][Full Text] [Related]
31. ΔNp63α facilitates proliferation and migration, and modulates the chromatin landscape in intrahepatic cholangiocarcinoma cells.
Peng A; Lin X; Yang Q; Sun Y; Chen R; Liu B; Yu X
Cell Death Dis; 2023 Nov; 14(11):777. PubMed ID: 38012140
[TBL] [Abstract][Full Text] [Related]
32. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis.
Clements O; Eliahoo J; Kim JU; Taylor-Robinson SD; Khan SA
J Hepatol; 2020 Jan; 72(1):95-103. PubMed ID: 31536748
[TBL] [Abstract][Full Text] [Related]
33. Sulindac prevents carcinogen-induced intrahepatic cholangiocarcinoma formation in vivo.
Wentz SC; Yip-Schneider MT; Gage EA; Saxena R; Badve S; Schmidt CM
J Surg Res; 2009 Nov; 157(1):e87-95. PubMed ID: 19564027
[TBL] [Abstract][Full Text] [Related]
34. Fascin Overexpression Promotes Cholangiocarcinoma RBE Cell Proliferation, Migration, and Invasion.
Zhao H; Yang F; Zhao W; Zhang C; Liu J
Technol Cancer Res Treat; 2016 Apr; 15(2):322-33. PubMed ID: 25882880
[TBL] [Abstract][Full Text] [Related]
35. EIF3H stabilizes CCND1 to promotes intrahepatic cholangiocarcinoma progression via Wnt/β-catenin signaling.
Wei Y; Chen W; Li Z; Xie K; Liu F
FASEB J; 2022 Dec; 36(12):e22647. PubMed ID: 36350008
[TBL] [Abstract][Full Text] [Related]
36. Incremental value of volumetric multiparametric MRI over Fudan score for prognosis of unresectable intrahepatic cholangiocarcinoma treated with systemic chemotherapy.
Pandey A; Mohseni A; Shaghaghi M; Pandey P; Rezvani Habibabadi R; Hazhirkarzar B; Ly A; Panid Madani S; Borhani A; Kamel IR
Eur J Radiol; 2024 Jan; 170():111196. PubMed ID: 38029705
[TBL] [Abstract][Full Text] [Related]
37. An immunostaining panel of C-reactive protein, N-cadherin, and S100 calcium binding protein P is useful for intrahepatic cholangiocarcinoma subtyping.
Akita M; Sawada R; Komatsu M; Suleman N; Itoh T; Ajiki T; Heaton N; Fukumoto T; Zen Y
Hum Pathol; 2021 Mar; 109():45-52. PubMed ID: 33321161
[TBL] [Abstract][Full Text] [Related]
38. Mitogen-activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial-mesenchymal transition.
Yang LX; Gao Q; Shi JY; Wang ZC; Zhang Y; Gao PT; Wang XY; Shi YH; Ke AW; Shi GM; Cai JB; Liu WR; Duan M; Zhao YJ; Ji Y; Gao DM; Zhu K; Zhou J; Qiu SJ; Cao Y; Tang QQ; Fan J
Hepatology; 2015 Dec; 62(6):1804-16. PubMed ID: 26340507
[TBL] [Abstract][Full Text] [Related]
39. Lipopolysaccharide activates nuclear factor-kappaB through toll-like receptors and related molecules in cultured biliary epithelial cells.
Harada K; Ohira S; Isse K; Ozaki S; Zen Y; Sato Y; Nakanuma Y
Lab Invest; 2003 Nov; 83(11):1657-67. PubMed ID: 14615419
[TBL] [Abstract][Full Text] [Related]
40. Aldehyde dehydrogenase 3B2 promotes the proliferation and invasion of cholangiocarcinoma by increasing Integrin Beta 1 expression.
Wang Y; Li K; Zhao W; Liu Z; Liu J; Shi A; Chen T; Mu W; Xu Y; Pan C; Zhang Z
Cell Death Dis; 2021 Dec; 12(12):1158. PubMed ID: 34907179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
